Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione [3]

Diabetologia

Volumn 49, Issue 9, 2006, Pages 2217-2218

  Emoto, M ^a   Fukuda, N ^a   Nakamori, Y ^a   Taguchi, A ^a   Okuya, S ^a   Oka, Y ^b   Tanizawa, Y ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; PIOGLITAZONE; SULFONYLUREA; TROGLITAZONE; VASCULOTROPIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; BODY FAT; CAPILLARY PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODILUTION; HUMAN; HYPERVOLEMIA; LETTER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; EDEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746690404     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0313-5     Document Type: Letter

References (9)

1. Guan Y, Hao C, Cha DR et al (2005) Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866
2. Williams GH, Dluhy RG (2005) Disorders of the adrenal cortex. In: Kasper DL et al. (eds) Harrison's principles of internal medicine, 16th edn. McGraw-Hill, New York, pp 2138-2140
3. Bartter FC, Schwartz WB (1967) The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42:790-806
4. Emoto M, Anno T, Sato Y et al (2001) Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 50:1166-1170
5. Kelly IE, Han TS, Walsh K, Lean ME (1999) Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293
6. Hollenberg NK (2003) Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115 (Suppl 8A):111S-115S
7. Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497-504
8. Baba T, Shimada K, Neugebauer S et al (2001) The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 24:953-954
9. Tooke JE, Elston LM, Gooding KM et al (2006) The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin. Diabetologia 49:1064-1070